Danaher Partners with IGI, Doudna, & Urnov, on Beacon for CRISPR Cures
By GEN,
Genetic Engineering and Biotechnology News
| 01. 11. 2024
The future of CRISPR-based therapies received a windfall this week with the launch of the Danaher-IGI Beacon for CRISPR Cures. The goal of the center is to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development, and regulatory approach. The Beacon for CRISPR Cures plans to do this by developing platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses. The model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract funding.
The center brings together a triple-threat of resources, from academia and industry, with the hope of making a tectonic shift in the field of CRISPR-based cures. The first of the three comes from industry. Danaher consists of many (more than 15) diverse businesses: Integrated DNA Technologies (IDT), Cytiva, Molecular Devices, Leica, Beckman Coulter, and Aldevron, to name a few. Danaher will make available an extensive collection of technologies and solutions for the manufacturing of CRISPR-based therapies and will also work to develop new technologies and...
Related Articles
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Simar Bajaj, The New York Times | 11.27.2025
A common cold was enough to kill Cora Oakley.
Born in Morristown, N.J., with virtually no immune system, Cora was diagnosed with severe combined immunodeficiency, a rare genetic condition that leaves the body without key white blood cells.
It’s better...
